KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to -$702.0 million.

  • Halozyme Therapeutics' Enterprise Value fell 535.14% to -$702.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$702.0 million, marking a year-over-year decrease of 535.14%. This contributed to the annual value of -$596.1 million for FY2024, which is 7740.3% down from last year.
  • Halozyme Therapeutics' Enterprise Value amounted to -$702.0 million in Q3 2025, which was down 535.14% from -$548.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Enterprise Value high stood at -$209.4 million for Q2 2022, and its period low was -$815.9 million during Q3 2021.
  • Its 5-year average for Enterprise Value is -$547.2 million, with a median of -$548.2 million in 2025.
  • As far as peak fluctuations go, Halozyme Therapeutics' Enterprise Value plummeted by 13533.48% in 2021, and later skyrocketed by 7228.15% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Enterprise Value (Quarter) stood at -$740.9 million in 2021, then surged by 51.03% to -$362.8 million in 2022, then grew by 7.39% to -$336.0 million in 2023, then crashed by 77.4% to -$596.1 million in 2024, then fell by 17.76% to -$702.0 million in 2025.
  • Its Enterprise Value stands at -$702.0 million for Q3 2025, versus -$548.2 million for Q2 2025 and -$747.9 million for Q1 2025.